Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Recurrence 1Pheochromocytoma 1Paraganglioma 1Neoplasms by Histologic Type 1Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lymphatic Diseases 1Immunoproliferative Disorders 1Immune System Diseases 1Gastro-enteropancreatic neuroendocrine tumor 1AIDS-Related Complex 1

Interventions

3-Iodobenzylguanidine 3cabozantinib 2tipifarnib 1pembrolizumab 1pazopanib 1lutetium Lu 177 dotatate 1lenvatinib 1guadecitabine 1fostamatinib 1copper dotatate CU-64 1atezolizumab 1Temozolomide 1Surgical Procedures, Operative 1Sunitinib 1Phenoxybenzamine 1Nivolumab 1Lutetium-177 1Lutetium 1Iodine-131 1Everolimus 1Erlotinib Hydrochloride 1Doxazosin 1Capecitabine 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Pheochromocytoma × Lutetium × Clear all
NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡